RNS Number : 1055G
Polarean Imaging PLC
25 April 2025
25 April 2025
Polarean Imaging Plc
("Polarean" or the "Company")
Notice of results
Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, confirms that it will be announcing its full year results for the year ended 30 December 2024 on Thursday, 8 May 2025.
Christopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation relating to the results via the Investor Meet Company platform on Thursday, 8 May 2025 at 15.00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your IMC dashboard up until 9.00 BST the day before the meeting or in real time during the presentation.
Investors can sign up to Investor Meet Company for free and add to meet Polarean Imaging Plc here. Investors who already follow Polarean on the Investor Meet Company platform will automatically be invited.
Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.
Enquiries:
Polarean Imaging Plc
www.polarean.com/ www.polarean-ir.com
Christopher von Jako, PhD, Chief Executive Officer
Via Walbrook PR
Charles Osborne, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)
+44 (0)20 7710 7600
Nicholas Moore / Nick Harland / Brough Ransom / Ben Good
Walbrook PR
Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Paul McManus
Mob: +44 (0)7876 741 001 / +44 (0) 7980 541 893
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORKZGZDFDRGKZM
